Elevated IgA antiphospholipid antibodies in healthy pregnant women in Sudan but not Sweden,without corresponding increase in IgA anti-β 2 glycoprotein I domain 1 antibodies

Abstract

Objective

The role of antiphospholipid antibodies (aPL) during apparently normal pregnancy is still unclear. IgA aPL are prevalent in populations of African origin. Our aim was to measure all isotypes of anticardiolipin (anti-CL) and anti–β₂ glycoprotein I (anti-β₂GPI) in healthy pregnant and non-pregnant women of different ethnicities.

Methods

Healthy Sudanese pregnant women (n = 165; 53 sampled shortly after delivery), 96 age-matched Sudanese female controls and 42 healthy pregnant and 249 non-pregnant Swedish women were included. IgA/G/M anti-CL and anti-β₂GPI were tested at one time point only with two independent assays in Sudanese and serially in pregnant Swedes. IgA anti-β₂GPI domain 1 and as controls IgA/G/M rheumatoid factor (RF), IgG anti–cyclic citrullinated peptide 2 (anti-CCP2) and anti–thyroid peroxidase (anti-TPO) were investigated in Sudanese females.

Results

Pregnant Sudanese women had significantly higher median levels of IgA anti-CL, IgA anti-β₂GPI (p < 0.0001 for both antibodies using two assays) and IgM anti-β₂GPI (both assays; p < 0.0001 and 0.008) compared with non-pregnant Sudanese. IgA anti-CL and anti-β₂GPI occurrence was increased among Sudanese pregnant women compared with national controls. No corresponding increase during pregnancy was found for IgA anti-β₂GPI domain 1 antibodies. Both IgG anti-CL and IgG control autoantibodies decreased during and directly after pregnancy among Sudanese. Serially followed Swedish women showed no changes in IgA aPL, whereas IgG/M anti-CL decreased.

Conclusions

IgA aPL are increased in Sudanese but not in Swedish women, without corresponding increase in IgA domain 1. Whether due to ethnicity and/or environmental influences the occurrence of IgA aPL during Sudanese pregnancies, and its clinical significance, is yet to be determined.

Keywords

Antiphospholipid antibodies IgA pregnancy healthy Sudan Africa

Introduction

Antiphospholipid antibodies (aPL) are well-recognized as the most common acquired and treatable risk factor for recurrent fetal loss.¹ β₂ glycoprotein I (β₂GPI) is frequently described as the main culprit antigen in antiphospholipid syndrome (APS) including aPL-induced pregnancy morbidity.^2,3 As suggested by previous in vivo and in vitro studies, different aPL-mediated mechanisms are involved in the pathogenesis of pregnancy-related complications and fetal loss. These mechanisms include placental tissue thrombosis and inflammation, distorted trophoblastic function and growth and complement activation.^4–6 Autoantibodies against domain 1 of β₂GPI (β₂GPI-D1) in particular have been shown to be associated with thrombotic events as compared with other epitopes.^7,8

According to the current Sapporo classification criteria APS includes only IgG and IgM but not IgA as isotypes for anticardiolipin (anti-CL) and anti-β₂GPI testing.¹ The latest international task force in 2014 found low degree of evidence for including IgA aPL in the classification criteria.⁹ Nevertheless, previous reports have indicated the considerable prevalence and clinical significance of IgA aPL in relation to obstetric adverse events, fetal demise and thrombosis in systemic lupus erythematosus (SLE) and/or APS.^10–15 Among Caucasian SLE patients there is a clear preponderance for IgG aPL, whereas a parallel IgA aPL preponderance was observed among African American SLE^16,17 and APS patients.¹⁸ Importantly, a previous paper from South Africa has reported that SLE patients with secondary APS showed the strongest association with IgA aPL,¹⁹ and in another study including 73 Kuwaiti women of Arabic ancestry both IgA and IgM but not IgG aPL associated with recurrent spontaneous abortions.¹⁰ It is noteworthy that IgA aPL was added to the 2012 Systemic Lupus International Collaborating Clinics/American College of Rheumatology criteria for SLE classification.²⁰

Pregnancy is a unique physiological and immunological state that is characterized by different biological changes to favor the environment and reception of the fetus.²¹ Changes of immunoglobulin isotype levels during normal pregnancy have been shown in early studies consistently reporting a drop in IgG and fluctuations in IgA and IgM levels as compared with pre-pregnancy state.^22–25 Previous papers documented decrease of aPL towards the end of pregnancy, with levels mostly within the pre-pregnancy reference range.^26,27 However, Lynch et al. have demonstrated that high levels of IgG anti-CL at the first antenatal visit before 25 weeks gestation correlated to fetal loss, and in a later longitudinal study they reported significant variations in IgG anti-CL levels during normal pregnancy, but repeated measurements of aPL did not add to risk stratification of these pregnancies.^28,29

Many reports addressing the role and clinical impact of IgG and IgM aPL in normal pregnancies and in obstetric APS have been published previously.^2,9,28,30 Data on the prevalence and significance of IgA aPL are, however, limited and almost completely lacking in populations of African origin. Given the special interest of IgA aPL in these populations, our goal was to investigate the occurrence of aPL isotypes during apparently healthy pregnancies in Sudan. As comparators, we also investigated healthy non-pregnant women from Sudan and healthy pregnant and non-pregnant women from Sweden. In Sudanese women we also investigated other autoantibodies: rheumatoid factor (RF) of all three isotypes, IgG anti–cyclic citrullinated peptide 2 (anti-CCP2) and IgG anti–thyroid peroxidase (anti-TPO).

Patients and methods

Participants

This study included 165 healthy pregnant and 96 healthy non-pregnant Sudanese women. Fifty-three of the pregnant women were sampled shortly (up to 6 h) after delivery. They were compared with 42 healthy pregnant Swedish women followed serially, and 249 non-pregnant population controls from the Karolinska case-control SLE cohort. All participants gave oral and/or written informed consent to participate in the study that was performed in agreement with the Declaration of Helsinki. Approval was obtained from the Ethical Committees of Alribat University Hospital (11 April 2011) and Omdurman Military Hospital (25 May 2011) for the Sudanese subjects and from the Uppsala and Karolinska University Hospital Ethics Committees for the Swedish subjects.

All Sudanese females were included during 2013–2014. Pregnant women were recruited at Alribat University Hospital and Omdurman Military Hospital in Khartoum. Information about age, parity and gestational age was provided from medical records. Non-pregnant females were university employees and students at Al Neelain University in Khartoum. Median age in years (range) of the pregnant, non-pregnant and delivered Sudanese women were 31 (19–43), 29 (22–43) and 29 (19–39) years, respectively. Among the pregnant females, 16.5%, 21.1% and 62.4% were in the first, second and third trimesters, respectively. Median number of previous pregnancies of the pregnant women including the recently delivered was three. Venous blood was collected from all subjects, immediately centrifuged, then separated, and the serum was stored at −70℃. Serum samples were available from 107 pregnant, 95 non-pregnant and 53 delivered females.

Healthy Swedish pregnant women were enrolled during 2004–2007 in Karlstad, Sweden as previously described.³¹ Median age (range) for the pregnant women was 28 (21–37) years, and 26, 13 and 1 females were in the first, second and third pregnancy, respectively. Plasma samples were available from 38 women and were serially collected at four time points corresponding to each trimester with the last two being at early and late third trimester. As non-pregnant cross-sectional controls for Swedes, we have included 249 population-based females from the Karolinska case-control SLE cohort who have been recruited during 2004–2011.^32,33

This study was planned as a cross-sectional study; as a consequence of the unexpected immunological findings in the Sudanese cohort, inclusion and further analysis of the Swedish cohort was performed as a comparator.

Immunological testing

Quantification of autoantibody isotypes IgA, IgG and IgM anti-CL and anti-β₂GPI was performed using the EliA system based on fluorescence enzyme immunoassay (FEIA) on the Phadia 2500 instrument (Thermo Fisher Scientific, Uppsala, Sweden) according to the manufacturer’s instructions, and the same analyses were repeated for Sudanese females using the Aptiva system based on a particle-based multi-analyte technology (PMAT) (Inova Diagnostics, San Diego, CA, USA, research use only). Among the Sudanese subjects, IgA against β₂GPI-D1 were analyzed using modified QUANTA Flash β₂GPI-D1 chemiluminescence assay (BIO-FLASH, Inova Diagnostics, research use only³⁴); control autoantibodies IgA, IgG and IgM RF, IgG anti-CCP2 and IgG anti-TPO were determined with FEIA (Thermo Fisher Scientific). Analysis of autoantibodies in plasma and serum specimens yielded similar results using the Thermo Fisher system (internal study from Thermo Fisher Scientific, Phadia GmbH). Lupus anticoagulant test was not performed in the Sudanese cohort due to unfeasibility to conform to sample collection and processing guidelines at the time of recruitment of subjects.

Three cut-offs were evaluated for each aPL isotype: the manufacturers’ suggested values, and the 95th and the 99th percentiles of the respective national non-pregnant women.

Statistical analysis

For comparisons between quantitative variables between several groups, Kruskal–Wallis test was performed, and whenever significant it was followed by Mann–Whitney U test for each pair. Chi-squared test was conducted to test for differences between categorical variables with Fisher’s exact test applied when appropriate. For paired quantitative variables Wilcoxon signed rank test was used. All statistical analyses including national cut-off calculations were conducted using JMP statistical software (SAS Institute, Cary, NC, USA). All p-values <0.05 were considered significant.

Results

Median levels of IgA anti-CL and IgA anti-β₂GPI (p < 0.0001 for both antibodies using two assays) and IgM anti-β₂GPI (both assays; p < 0.0001 and 0.008) were higher among pregnant than among non-pregnant Sudanese women. These differences were evident also when comparing the recently delivered with non-pregnant women (Figures 1 and 2). Median IgA aPL levels in post-partum females were higher compared with pregnant women, although not statistically significant. IgG anti-CL levels on the other hand were lower during pregnancy and shortly after childbirth as compared with non-pregnant women (p = 0.02 and p = 0.01; Figure 1). Median levels did not differ for any aPL between the 42 pregnant women in the last gestation month and post-partum women (data not shown). Very similar results were obtained using FEIA (Figure 1) and PMAT (Figure 2). Using all three cut-offs, the occurrence of IgA anti-CL and anti-β₂GPI tested by both assays was significantly higher in pregnant compared with non-pregnant Sudanese women (Tables 1 and 2), whereas IgM anti-β₂GPI showed higher prevalence among pregnant females when using the 95th Sudanese national cut-off in FEIA (Table 1), but not using PMAT.

Figure 1

Levels of IgA/G/M anticardiolipin (anti-CL) and anti–β₂ glycoprotein I (anti-β₂GPI) antibodies tested with fluorescence enzyme immunoassay among Sudanese women. (a), (c) and (e) IgA/G/M anti-CL and (b), (d) and (f) IgA/G/M anti-β₂GPI levels among healthy non-pregnant, pregnant and recently delivered females. Horizontal dotted lines represent the 95th and 99th percentiles among the healthy non-pregnant women. Comparisons between individual groups were made for those antibodies showing an overall significant difference between the three groups. *p < 0.05, **p < 0.01, ***p < 0.001, NS: not significant.

Figure 2

Levels of IgA/G/M anticardiolipin (anti-CL) and anti–β₂ glycoprotein I (anti-β₂GPI) antibodies tested with particle-based multi-analyte technology among Sudanese women. (a), (c) and (e) IgA/G/M anti-CL and (b), (d) and (f) IgA/G/M anti-β₂GPI levels among healthy non-pregnant, pregnant and recently delivered females. Horizontal dotted lines represent the 95th and 99th percentiles among the healthy non-pregnant women. Median fluorescence intensity (MFI) is a raw measurement unit and not a final calibrated unit. Comparisons between individual groups were made for those antibodies showing an overall significant difference between the three groups. *p < 0.05, **p < 0.01, ***p < 0.001, NS: not significant.

Table 1

Prevalence of anticardiolipin and anti–β₂ glycoprotein I isotypes tested with fluorescence enzyme immunoassay among healthy NP, pregnant and RD Sudanese females.

	NP n = 95 n (%)	Pregnant n = 107 n (%)	RD n = 53 n (%)	p-value (overall)	p-value (NP-pregnant)	p-value (NP-RD)	p-value (pregnant-RD)
IgA
CL 95th	4 (4.2)	31 (28.9)	15 (28.3)	<0.0001	<0.0001	<0.0001	0.9
CL 99th	0 (0)	17 (15.9)	11 (20.7)	<0.0001	<0.0001	<0.0001	0.4
CL Phadia	1 (1)	30 (28)	14 (26.4)	<0.0001	<0.0001	<0.0001	0.8
β₂GPI 95th	4 (4.2)	51 (47.7)	31 (58.5)	<0.0001	<0.0001	<0.0001	0.2
β₂GPI 99th	0 (0)	35 (32.7)	17 (32.1)	<0.0001	<0.0001	<0.0001	0.9
β₂GPI Phadia	15 (15.8)	64 (59.8)	40 (75.5)	<0.0001	<0.0001	<0.0001	0.05
IgG
CL 95th	4 (4.2)	4 (3.7)	2 (3.8)	0.9
CL 99th	0 (0)	0 (0)	0 (0)	NA
CL Phadia	2 (2.1)	1 (0.9)	1 (1.9)	0.9
β₂GPI 95th	4 (4.2)	1 (0.9)	1 (1.9)	0.3
β₂GPI 99th	0 (0)	0 (0)	1 (1.9)	0.1
β₂GPI Phadia	8 (8.4)	9 (8.4)	4 (7.6)	0.9
IgM
CL 95th	4 (4.2)	6 (5.6)	6 (11.3)	0.2
CL 99th	0 (0)	2 (1.9)	2 (3.8)	0.2
CL Phadia	1 (1)	3 (2.9)	3 (5.7)	0.3
β₂GPI 95th	4 (4.2)	15 (14.0)	10 (18.9)	0.01	0.02	0.003	0.4
β₂GPI 99th	0 (0)	5 (4.7)	4 (7.5)	0.04	0.06	0.01	0.5
β₂GPI Phadia	3 (3.2)	8 (7.5)	7 (13.2)	0.07

Occurrence of IgA, IgG and IgM anti-CL and anti-β₂GPI were compared using three cut-offs: individual national cut-offs based on the 95th and 99th percentiles among national controls and cut-offs as recommended by the manufacturer. Statistical comparisons between each of the two groups were performed when the overall comparison showed significant difference. Significant p-values are depicted in bold.

₂GPI: β₂ glycoprotein I; CL: cardiolipin; NP: non-pregnant; RD: recently delivered.

Table 2

Prevalence of anticardiolipin and anti–β₂ glycoprotein I isotypes tested with particle-based multi-analyte technology among healthy NP, pregnant and RD Sudanese females.

	NP n = 92 n (%)	Pregnant n = 109 n (%)	RD n = 53 n (%)	p-value (overall)	p-value (NP-pregnant)	p-value (NP-RD)	p-value (pregnant-RD)
IgA
CL 95th	4 (4.3)	55 (50.5)	26 (50)	<0.0001	<0.0001	<0.0001	0.9
CL 99th	0 (0)	37 (33.9)	15 (28.8)	<0.0001	<0.0001	<0.0001	0.5
CL Inova	3 (3.3)	47 (43.1)	23 (44.2)	<0.0001	<0.0001	<0.0001	0.9
β₂GPI 95th	4 (4.3)	49 (44.9)	27 (51.9)	<0.0001	<0.0001	<0.0001	0.4
β₂GPI 99th	0 (0)	37 (33.9)	16 (30.8)	<0.0001	<0.0001	<0.0001	0.7
β₂GPI Inova	8 (8.7)	66 (60.5)	37 (71.1)	<0.0001	<0.0001	<0.0001	0.2
IgG
CL 95th	4 (4.3)	5 (4.6)	2 (3.8)	0.9
CL 99th	0 (0)	2 (1.8)	0 (0)	0.3
CL Inova	1 (1.1)	3 (2.7)	1 (1.9)	0.7
β₂GPI 95th	4 (4.3)	2 (1.3)	1 (1.9)	0.5
β₂GPI 99th	0 (0)	1 (0.9)	0 (0)	0.5
β₂GPI Inova	2 (2.2)	1 (0.9)	1 (1.9)	0.7
IgM
CL 95th	4 (4.4)	5 (4.7)	4 (7.8)	0.6
CL 99th	0 (0)	2 (1.9)	2 (3.9)	0.2
CL Inova	0 (0)	1 (0.9)	1 (1.9)	0.4
β₂GPI 95th	4 (4.4)	9 (8.4)	6 (11.8)	0.3
β₂GPI 99th	0 (0)	1 (0.9)	2 (3.9)	0.1
β₂GPI Inova	0 (0)	1 (0.9)	2 (3.9)	0.1

β₂GPI: β₂ glycoprotein I; CL: cardiolipin; NP: non-pregnant; RD: recently delivered.

IgA and IgM RF did not differ between non-pregnant, pregnant and recently delivered women, whereas levels of IgG RF, IgG anti-CCP2 and IgG anti-TPO were lower in the pregnant and recently delivered groups (Figure 3(a), (c) to (f)). Levels of IgA antibodies against β₂GPI-D1 did not differ between the groups (Figure 3(b)).

Figure 3

Levels of control antibodies and anti–β₂ glycoprotein I domain 1 antibodies among Sudanese women. (a), (c) and (e) IgA/G/M rheumatoid factor (RF), (b) IgA anti–domain 1, (d) IgG anti–cyclic citrullinated peptide 2 (anti-CCP2) and (f) IgG anti–thyroid peroxidase (anti-TPO) among healthy non-pregnant, pregnant and recently delivered Sudanese females. Horizontal dotted lines represent the 95th and 99th percentiles among the healthy non-pregnant women. One healthy non-pregnant subject has anti-TPO outside the graph range, not shown in the figure but included in the statistics. Relative light unit (RLU) in panel (b) is a raw measurement unit and not a final calibrated unit. Comparisons between individual groups were made for those antibodies showing an overall significant difference between the three groups. *p < 0.05, **p < 0.01, ***p < 0.001, NS: not significant.

After stratifying the pregnant Sudanese women in relation to pregnancy duration at the time of blood sampling, IgM anti-β₂GPI levels were higher during the second trimester compared with the first trimester (4.0 versus 2.3 ELIA U/ml, p = 0.007; FEIA); otherwise there were no differences for any aPL with both assays. Sudanese women’s parity did not show any associations to the levels of any aPL (data not shown).

Among the serially followed Swedish pregnant women, there were no fluctuations in IgA anti-CL or IgA, IgG and IgM anti-β₂GPI during pregnancy; however, compared with the first trimester levels anti-CL dropped in the second and third trimesters for IgG and in the third trimester for IgM (p = 0.03 and p = 0.007 and p = 0.0006, respectively; Figure 4). Occurrence of aPL did not differ between Swedish pregnant women and Swedish non-pregnant controls; this concerned all isotypes and all trimesters investigated separately (data not shown).

Figure 4

Serial measurements of IgA/G/M anticardiolipin (anti-CL) and anti–β₂ glycoprotein I (anti-β₂GPI) antibodies during normal pregnancies of Swedish women. (a), (c) and (e) IgA/G/M anti-CL and (b), (d) and (f) IgA/G/M anti-β₂GPI levels among 42 healthy pregnant Swedish women investigated during the first, second, early third and late third trimesters that are represented in gestational weeks (GW). Below each panel, median antibody levels are shown for the first, second and early third trimester time points. Horizontal lines represent the cut-offs for clearly positive reactivity, as recommended by the manufacturer. Comparisons were made against first trimester. *p < 0.05, **p < 0.01, ***p < 0.001, NS: not significant.

Discussion

In this study we detected elevated levels and increased occurrence of both IgA anti-CL and IgA anti-β₂GPI among Sudanese pregnant women (15.9% and 32.7%, respectively). A similar trend was also seen for IgM anti-β₂GPI using one assay. Such differences were not observed in Swedish pregnant women.

The number of non-pregnant Sudanese controls was limited (95 and 92 serum samples were available for FEIA and PMAT, respectively). Although these numbers are less than what is recommended by the International Society on Thrombosis and Haemostasis³⁵ to calculate the 99th country-based cut-off for aPL, comparisons using the 99th cut-off among Sudanese women yielded similar findings as the 95th national cut-offs and company suggested cut-offs. It is noteworthy that previous studies have described low-titer aPL (>95th and <99th percentile) rather than high-titer (>99th) to be more clinically significant for obstetric APS.^36,37

Prevalence of aPL in healthy asymptomatic individuals is 1–5% for anti-CL and 3% for anti-β₂GPI.³⁸ The predictive value for APS clinical events in asymptomatic carriers has been addressed by few studies. In an old study from 1996 on 1600 healthy pregnant women who were followed up during pregnancy and after delivery, the authors showed that women with IgG anti-CL had increased risk for pre-eclampsia, fetal growth retardation and fetal demise compared with sero-negative women.³⁹ Lynch et al. also reported a similar conclusion, where high IgG anti-CL in early pregnancy could predict adverse pregnancy outcomes.²⁸ Moreover, in agreement with these studies, Faden et al. demonstrated in a prospective cohort that IgG and/or IgM anti-β₂GPI were associated with pre-eclampsia or eclampsia in healthy pregnant females even if other anti-CL isotypes were not present.⁴⁰ Interestingly, Tortosa et al. recently reported that individuals with isolated IgA anti-β₂GPI but without history of APS events had more APS-related events, mainly arterial thrombosis, during 5-year follow-up compared with individuals negative for aPL.⁴¹ However, it is noteworthy that risk stratification using the antiphospholipid score (aPL-S)⁴² and/or the global APS score (GAPSS)⁴³ does not involve IgA aPL. These two scoring systems have been described as inconclusive for assessment of pregnancy morbidity risk.⁴⁴ In the current study, for logistic reasons we were not able to obtain information regarding the outcome of pregnancies in Sudanese women. However, it was documented that all women had normal previous pregnancies that ended in delivering healthy live births.

IgA has been described to be the most prevalent aPL isotype in populations of African origin.^10,16–19 In parallel, our group recently reported a predominance of IgA RF in Sudanese rheumatoid arthritis patients.⁴⁵ In the current study, the high levels and prevalence of IgA anti-CL and anti-β₂GPI in Sudanese pregnant females was not associated with increased IgA RF levels, arguing against a general IgA increase in these women but instead indicating an antigen-specific increase in IgA aPL. Interestingly, when comparing Swedish pregnant with non-pregnant women as well as serially investigating anti-CL and anti-β₂GPI autoantibodies throughout Swedish normal pregnancies we could not observe increase in any aPL, including the IgA isotype. Thus, the increased IgA aPL levels seem to be characteristic for pregnancies in Sudan. We cannot from the current study disentangle if the origin is genetic or environmental. Genetic investigation of this Sudanese cohort is planned.

Our finding of lower levels of IgG autoantibodies in Sudanese pregnant compared with non-pregnant women as well as late drop of IgG aPL in serially followed pregnant Swedes agree with previous studies showing general decrease of total IgG during normal pregnancies,^22–24 which can be explained by the concomitant physiological changes as plasma volume expansion and/or passage of IgG through the placenta to the fetus. Additionally, in the PROMISSE study on patients with SLE and/or APS, Yelnik et al. reported a decrease in IgG anti-CL and anti-β₂GPI levels during the second and third trimester as compared with early pregnancy, although these changes in aPL levels did not predict pregnancy outcomes.⁴⁶

To date, we do not know the clinical importance of this increase in IgA aPL during apparently healthy Sudanese pregnancies. In 2006, the worldwide stillbirth rate was calculated to be 23.9 stillbirths per 1000 deliveries, with the highest incidence in sub-Saharan Africa (32.2/1000) that is far higher than in the developed countries (5.3/1000).⁴⁷ During 2010–2011, 2.16% (106/4895) of all deliveries at Soba University Hospital in Khartoum, Sudan resulted in stillbirths (Sahwa Elbagir, personal communication). It is important to find out if unrecognized increase in IgA aPL during pregnancy can explain part of these fatalities, in which case testing for IgA aPL during normal pregnancies would be of clinical importance. It is known from previous studies that persistently high aPL levels is associated with unfavorable pregnancy outcomes.⁴⁸

The β₂GPI molecule consists of five domains, where IgG and IgM antibodies against the outmost domain 1 are considered to be especially associated with pregnancy morbidity and fetal loss.^7,8,49,50 After obtaining our results showing the striking IgA reactivity against CL and β₂GPI in Sudanese pregnant women using one brand of reagents, the study was extended with repeated analyses of the conventional aPL including IgA antibodies specifically directed against β₂GPI-D1, using reagents and technology provided by another company. The repeated analyses showed essentially identical results with both test systems, replicating the increase in IgA aPL and IgM anti-β₂GPI in pregnant Sudanese women. However, we did not observe a corresponding increase in levels of IgA anti-β₂GPI-D1 antibodies among the Sudanese pregnant women, and median levels were essentially similar among non-pregnant and pregnant women as well as those recently delivered. The literature on domain specificity for IgA anti-β₂GPI autoantibodies is considerably scarce compared with conventional IgG and IgM autoantibodies. Despierres et al. reported that IgA antibodies against domain 4/5 associated with SLE without thrombosis whereas IgA anti-β₂GPI-D1 was not associated with thrombosis or SLE.⁵¹ These data are corroborated by a recent report showing that IgA anti-β₂GPI from patients with thrombotic APS do not mainly bind domain 1, but instead target three sites in domains 3, 4 and 5.⁵² Monoclonal antibodies against these epitopes have previously been shown to produce APS in animal models.⁵³ Murthy et al. investigated three multi-ethnic cohorts and showed high correlation between IgA anti-β₂GPI and IgA anti–domain 4/5 levels, as well as occurrence of thrombotic events and pregnancy losses in 77% of patients positive for anti-β₂GPI domain 4/5 antibodies.¹⁵ Consequently, β₂GPI-D1 might not be the major target for pathological IgA anti-β₂GPI, and the non-reactivity against domain 1 of the aPL found in Sudanese pregnant women cannot be interpreted as a clear sign for non-pathogenicity of IgA aPL in this context. Further studies are warranted.

The current study is, to the best of our knowledge, the first report showing increased prevalence of IgA aPL in healthy pregnant African women, a finding that was not observed in the Swedish population. A limitation to this study is the cross-sectional design and the lack of follow-up of pregnancy outcomes and aPL levels which could have enabled us to stratify risk for maternal and fetal morbidity and mortality. Also, sampling was performed only once and not in agreement with the current Sapporo classification criteria for APS.¹ As our current findings of increased IgA aPL during Sudanese normal pregnancies were unexpected, we regard this study as hypothesis generating. To understand if and when during pregnancy IgA aPL should be investigated, and whether single or repeated testing may be needed, asymptomatic pregnancies in Sudanese women should be followed serially both concerning aPL levels and clinical outcome.

Footnotes

Acknowledgements

We thank Maryam Poorafshar at Thermo Fisher Scientific and Silvia Casas and Michael Mahler at Inova Diagnostics who provided laboratory reagents, access to assay equipment and manpower for autoantibody analyses.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Swedish Rheumatism Association, King Gustav Vth 80 Years Foundation, the Uppsala County Council, the Signe and Reinhold Sund Foundation for Rheumatology Research, and the Agnes and Mac Rudberg Foundation.

ORCID iD

S Elbagir

References

Miyakis

Lockshin

Atsumi

, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.

Meroni

Borghi

Raschi

Tedesco

. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011; 7: 330–339.

de Laat

Derksen

Urbanus

Roest

de Groot

. beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004; 104: 3598–3602.

Peaceman

Rehnberg

. The effect of immunoglobulin G fractions from patients with lupus anticoagulant on placental prostacyclin and thromboxane production. Am J Obstet Gynecol 1993; 169: 1403–1406.

Berman

Girardi

Salmon

. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005; 174: 485–490.

Thurman

Kraus

Girardi

, et al. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol 2005; 42: 87–97.

Mahler

Norman

Meroni

Khamashta

. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev 2012; 12: 313–317.

de Laat

Derksen

Urbanus

de Groot

. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105: 1540–1545.

Bertolaccini

Amengual

Andreoli

, et al. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 2014; 13: 917–930.

10.

Bahar

Kwak

Beer

, et al. Antibodies to phospholipids and nuclear antigens in non-pregnant women with unexplained spontaneous recurrent abortions. J Reprod Immunol 1993; 24: 213–222.

11.

Yamada

Tsutsumi

Ichikawa

Kato

Koike

Fujimoto

. IgA-class anti-beta2-glycoprotein I in women with unexplained recurrent spontaneous abortion. Arthritis Rheum 1999; 42: 2727–2728.

12.

Lee

Branch

Silver

. Immunoglobulin A anti-beta2-glycoprotein antibodies in women who experience unexplained recurrent spontaneous abortion and unexplained fetal death. Am J Obstet Gynecol 2001; 185: 748–753.

13.

Carmo-Pereira

Bertolaccini

Escudero-Contreras

Khamashta

Hughes

. Value of IgA anticardiolipin and anti-beta2-glycoprotein I antibody testing in patients with pregnancy morbidity. Ann Rheum Dis 2003; 62: 540–543.

14.

Lopez

Santos

Espinoza

La Rosa

. Clinical significance of immunoglobulin A versus immunoglobulins G and M anti-cardiolipin antibodies in patients with systemic lupus erythematosus. Correlation with thrombosis, thrombocytopenia, and recurrent abortion. Am J Clin Pathol 1992; 98: 449–454.

15.

Murthy

Willis

Romay-Penabad

, et al. Value of isolated IgA anti-beta2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum 2013; 65: 3186–3193.

16.

Cucurull

Gharavi

Diri

Mendez

Kapoor

Espinoza

. IgA anticardiolipin and anti-beta2-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus. Am J Med Sci 1999; 318: 55–60.

17.

Mehrani

Petri

. Association of IgA Anti-beta2 glycoprotein I with clinical and laboratory manifestations of systemic lupus erythematosus. J Rheumatol 2011; 38: 64–68.

18.

Diri

Cucurull

Gharavi

, et al. Antiphospholipid (Hughes’) syndrome in African-Americans: IgA aCL and abeta2 glycoprotein-I is the most frequent isotype. Lupus 1999; 8: 263–268.

19.

Gould

Tikly

Asherson

Loizou

Singh

. Prevalence and clinical correlates of anti-phospholipid antibodies in South Africans with systemic lupus erythematosus. Scand J Rheumatol 2006; 35: 29–34.

20.

Petri

Orbai

Alarcon

, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686.

21.

Chaouat

. The Th1/Th2 paradigm: still important in pregnancy? Semin Immunopathol 2007; 29: 95–113.

22.

Klobasa

Habe

Werhahn

Butler

. Changes in the concentrations of serum IgG, IgA and IgM of sows throughout the reproductive cycle. Vet Immunol Immunopathol 1985; 10: 341–353.

23.

Yasuhara

Tamaki

Iyama

Yamaguchi

Tachi

Amino

. Reciprocal changes in serum levels of immunoglobulins (IgG, IgA, IgM) and complements (C3, C4) in normal pregnancy and after delivery. J Clin Lab Immunol 1992; 38: 137–141.

24.

Larsson

Palm

Hansson

Basu

Axelsson

. Reference values for alpha1-acid glycoprotein, alpha1-antitrypsin, albumin, haptoglobin, C-reactive protein, IgA, IgG and IgM during pregnancy. Acta Obstet Gynecol Scand 2008; 87: 1084–1088.

25.

Miller

Abel

. [Changes in the immunoglobulins IgG, IgA and IgM in pregnancy and the puerperium]. Zentralbl Gynakol 1984; 106: 1084–1091.

26.

Tsapanos

Kanellopoulos

Cardamakis

, et al. Anticardiolipin antibodies levels in healthy pregnant and non-pregnant woman. Arch Gynecol Obstet 2000; 263: 111–115.

27.

Karagjozova

Tchernev

Baleva

. [Antibodies against phospholipids in patients with normal pregnancy]. Akush Ginekol (Sofiia) 2013; 52: 3–6.

28.

Lynch

Marlar

Murphy

, et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study. Ann Intern Med 1994; 120: 470–475.

29.

Lynch

Rutledge

Stephens

, et al. Longitudinal measurement of anticardiolipin antibodies during normal pregnancy: a prospective study. Lupus 1995; 4: 365–369.

30.

Kelchtermans

Pelkmans

de Laat

Devreese

. IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis. J Thromb Haemost 2016; 14: 1530–1548.

31.

Wikström

Ekegren

Karlsson

Wikström

Bergenheim

Åkerud

. Plasma levels of S100B during pregnancy in women developing pre-eclampsia. Pregnancy Hypertens 2012; 2: 398–402.

32.

Grönwall

Hardt

Gustafsson

, et al. Depressed serum IgM levels in SLE are restricted to defined subgroups. Clin Immunol 2017; 183: 304–315.

33.

Idborg

Zandian

Sandberg

, et al. Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjogren’s syndrome differ in molecular signatures and treatment perspectives. Arthritis Res Ther 2019; 21: 62–62.

34.

Mahler

Albesa

Zohoury

, et al. Autoantibodies to domain 1 of beta 2 glycoprotein I determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome. Lupus 2016; 25: 911–916.

35.

Devreese

Pierangeli

de Laat

Tripodi

Atsumi

Ortel

. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost 2014; 12: 792–795.

36.

Boffa

Boinot

De Carolis

, et al. Laboratory criteria of the obstetrical antiphospholipid syndrome. Data from a multicentric prospective European women cohort. Thromb Haemost 2009; 102: 25–28.

37.

Gardiner

Hills

Machin

Cohen

. Diagnosis of antiphospholipid syndrome in routine clinical practice. Lupus 2013; 22: 18–25.

38.

Mehrani

Petri

Epidemiology of the antiphospholipid syndrome. In: Cervera

Reverter

Khamashta

(eds). Handbook of systemic autoimmune diseases, Elsevier, 2009, pp. 13–34.

39.

Katano

Aoki

Sasa

Ogasawara

Matsuura

Yagami

. beta 2-glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. Hum Reprod 1996; 11: 509–512.

40.

Faden

Tincani

Tanzi

, et al. Anti-beta 2 glycoprotein I antibodies in a general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome. Anti-beta2 glycoprotein I antibodies are associated with some obstetrical complications, mainly preeclampsia-eclampsia. Eur J Obstet Gynecol Reprod Biol 1997; 73: 37–42.

41.

Tortosa

Cabrera-Marante

Serrano

, et al. Incidence of thromboembolic events in asymptomatic carriers of IgA anti beta2 glycoprotein-I antibodies. PLoS One 2017; 12: e0178889–e0178889.

42.

Otomo

Atsumi

Amengual

, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 2012; 64: 504–512.

43.

Sciascia

Sanna

Murru

Roccatello

Khamashta

Bertolaccini

. GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford) 2013; 52: 1397–1403.

44.

Kato

Hisada

Atsumi

. Clinical profiles and risk assessment in patients with antiphospholipid antibodies. Expert Rev Clin Immunol 2019; 15: 73–81.

45.

Elshafie

Elbagir

Aledrissy

MIE

Elagib

Nur

MAM

Ronnelid

. Occurrence of anti-CCP2 and RF isotypes and their relation to age and disease severity among Sudanese patients with rheumatoid arthritis. Clin Rheumatol 2019; 38: 1545–1553.

46.

Yelnik

Porter

Branch

, et al. Brief report: changes in antiphospholipid antibody titers during pregnancy: effects on pregnancy outcomes. Arthritis Rheumatol 2016; 68: 1964–1969.

47.

Stanton

Lawn

Rahman

Wilczynska-Ketende

Hill

. Stillbirth rates: delivering estimates in 190 countries. Lancet 2006; 367: 1487–1494.

48.

Riancho-Zarrabeitia

Daroca

Munoz

Lopez-Hoyos

Haya

Martinez-Taboada

. Serological evolution in women with positive antiphospholipid antibodies. Semin Arthritis Rheum 2017; 47: 397–402.

49.

Chighizola

Pregnolato

Andreoli

, et al. Beyond thrombosis: anti-beta2GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome. J Autoimmun 2018; 90: 76–83.

50.

Chighizola

Gerosa

Meroni

. New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies. Curr Rheumatol Rep 2014; 16: 402–402.

51.

Despierres

Beziane

Kaplanski

, et al. Contribution of anti-beta2glycoprotein I IgA antibodies to the diagnosis of anti-phospholipid syndrome: potential interest of target domains to discriminate thrombotic and non-thrombotic patients. Rheumatology (Oxford) 2014; 53: 1215–1218.

52.

Serrano

Martinez-Flores

Norman

Naranjo

Morales

Serrano

. The IgA isotype of anti-beta2 glycoprotein I antibodies recognizes epitopes in domains 3, 4, and 5 that are located in a lateral zone of the molecule (L-shaped). Front Immunol 2019; 10: 1031–1031.

53.

Blank

Shoenfeld

Cabilly

Heldman

Fridkin

Katchalski-Katzir

. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci U S A 1999; 96: 5164–5168.